Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Total Non-Current Liabilities (2020 - 2025)

Historic Total Non-Current Liabilities for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to $9.2 million.

  • Insight Molecular Diagnostics' Total Non-Current Liabilities fell 2211.39% to $9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.2 million, marking a year-over-year decrease of 2211.39%. This contributed to the annual value of $9.6 million for FY2024, which is 261.76% up from last year.
  • As of Q3 2025, Insight Molecular Diagnostics' Total Non-Current Liabilities stood at $9.2 million, which was down 2211.39% from $8.5 million recorded in Q2 2025.
  • Insight Molecular Diagnostics' Total Non-Current Liabilities' 5-year high stood at $24.2 million during Q2 2021, with a 5-year trough of -$11.1 million in Q1 2023.
  • For the 5-year period, Insight Molecular Diagnostics' Total Non-Current Liabilities averaged around $11.8 million, with its median value being $11.3 million (2024).
  • As far as peak fluctuations go, Insight Molecular Diagnostics' Total Non-Current Liabilities tumbled by 16440.6% in 2023, and later surged by 19740.34% in 2024.
  • Quarter analysis of 5 years shows Insight Molecular Diagnostics' Total Non-Current Liabilities stood at $17.7 million in 2021, then dropped by 16.02% to $14.8 million in 2022, then plummeted by 36.65% to $9.4 million in 2023, then rose by 2.62% to $9.6 million in 2024, then fell by 4.72% to $9.2 million in 2025.
  • Its Total Non-Current Liabilities stands at $9.2 million for Q3 2025, versus $8.5 million for Q2 2025 and $11.8 million for Q1 2025.